Go back
Title: Clinical Utilization Of Fast-Acting Sub-Perception Therapy (FAST) In SCS-Implanted Patients For Treatment Of Mixed Nociceptive And Neuropathic Pain
e-poster Number: INSIM19
Category: Pain
Author Name: Georgios Matis
Institute: University Hospital Cologne, Cologne, Germany
Co-Author Name: Roshini Jain
Abstract :
Introduction: Patients implanted with Spinal Cord Stimulation (SCS) devices can exhibit mixed pain (nociceptive: pain derived from non-neuronal tissue and nociceptor activation; or, neuropathic: pain derived from lesion or disease that satisfies established neurological diagnostic criteria) but may present as challenging cases. A recent study reported discovery of a novel SCS methodology (FAST) capable of delivering therapeutic neurostimulation using a biphasic-symmetric waveform capable of inducing analgesia within minutes.
Aims/Objectives: We surmised that this new neurostimulative approach may help possibly improve outcomes in a population of SCS-implanted patients with mixed pain and report real-world preliminary experience in an observational, case-series.
Methods: This is a single-center, retrospective, observational case-series of patients demonstrating symptoms of mixed pain who were previously implanted with an SCS device and subsequently converted to a new system (Boston Scientific) capable of multiple independent current control (MICC) and fast-acting sub-perception therapy (FAST). Measured clinical assessments include the following: pain intensity scores (NRS, VAS), Oswestry Disability Index (ODI), reduction in opioid medication, and Quality-of-Life (EQ-5D). Collection of data is derived from patient assessment at pre-implant (baseline), end of trial, and 3-and 6-months follow-up.
Results: This study is currently on-going. Analyzed clinical outcomes will be presented..
Conclusions: Newly uncovered SCS methods, such as novel FAST, offer potential to re-address longstanding challenges treating patients with chronic pain. In particular, novel approaches may mediate analgesic responses via mechanisms that differ from traditional approaches, thus presenting the possibility for expanding the array of indications for which SCS may be successfully used (e.g. nociceptive syndromes).
